Grade My Investments
HomeFree Stock Grades › NPCE

NeuroPace, Inc. (NPCE) Stock Grade

NPCE · Healthcare

A+
Grade updated: July 18, 2026
Computed by the GradeMyInvestments scoring model from revenue growth, profitability, balance-sheet strength, and analyst targets.
Market Cap
$505.2M
P/E Ratio
Revenue Growth (YoY)
+25.1%
Net Margin
-21.5%
Return on Equity
Dividend Yield
None

About NeuroPace, Inc.'s fundamentals

NeuroPace is a medical device company with a market capitalization of $505.2 million that is experiencing strong revenue growth of 25.1% year-over-year. However, the company is currently unprofitable, operating at a net margin of -21.5% and reporting a net loss in its latest annual statement. The company does not pay a dividend, which is typical for growth-stage medical device companies reinvesting losses back into operations.

Track NPCE free — no credit card required. Live grade + monthly AI report →